Souan Lina, Abdel-Razeq Hikmat, Nashwan Sura, Al Badr Sara, Alrabi Kamal, Sughayer Maher A
Department of Pathology & Laboratory Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
Department of Medicine, King Hussein Cancer Center, Amman 11941, Jordan.
Vaccines (Basel). 2023 Oct 30;11(11):1659. doi: 10.3390/vaccines11111659.
The effective development of COVID-19 vaccination has mitigated its harm. Using two laboratory methods, we investigated the efficacy of the BNT162b2 mRNA and BBIBP-CorV COVID-19 vaccines on seroconversion rates in cancer patients undergoing active cancer treatment.
SARS-CoV-2 vaccines were scheduled for 134 individuals. The consenting participants submitted three venous blood samples. Three samples: T0, T1, and T2. The ABBOTT-SARS-CoV-2 IgG II Quant and Elecsys Anti-SARS-CoV-2 assays were used to evaluate the samples and convert the antibody titers to WHO (BAU)/mL units.
Cancer patients exhibited a higher seroconversion rate at T2, regardless of vaccination type, and the mean antibody titers at T1 and T2 were higher than those at T0. BBIBP-CorV patients required a booster because BNT162b2 showed a higher seroconversion rate between T0 and T1. Statistics indicate that comparing Abbott and Roche quantitative antibody results without considering the sample collection time is inaccurate.
COVID-19 vaccines can still induce a humoral immune response in patients undergoing cancer-targeted therapy. The strength of this study is the long-term monitoring of antibody levels after vaccination in cancer patients on active therapy using two different immunoassays. Further multicenter studies with a larger number of patients are required to validate these findings.
新型冠状病毒肺炎（COVID-19）疫苗的有效研发减轻了其危害。我们采用两种实验室方法，研究了BNT162b2 mRNA疫苗和BBIBP-CorV COVID-19疫苗对正在接受积极癌症治疗的癌症患者血清转化率的疗效。
为134名个体安排了严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫苗接种。同意参与的参与者提交了三份静脉血样本。三个样本分别为：T0、T1和T2。使用雅培SARS-CoV-2 IgG II定量检测法和电化学发光法抗SARS-CoV-2检测法对样本进行评估，并将抗体滴度换算为世界卫生组织（BAU）/mL单位。
无论接种何种疫苗，癌症患者在T2时的血清转化率均较高，且T1和T2时的平均抗体滴度高于T0时。接种BBIBP-CorV疫苗的患者需要加强接种，因为BNT162b2在T0和T1之间显示出较高的血清转化率。统计数据表明，在不考虑样本采集时间的情况下比较雅培和罗氏定量抗体结果是不准确的。
COVID-19疫苗仍可在接受癌症靶向治疗的患者中诱导体液免疫反应。本研究的优势在于使用两种不同的免疫检测方法对正在接受积极治疗的癌症患者接种疫苗后的抗体水平进行长期监测。需要进一步开展更多患者参与的多中心研究来验证这些发现。
